Back to the future: “7+3” joins the venetoclax plus intensive chemotherapy movement

Chinese Clinical Oncology · Published 2026-06-01 · DOI 10.21037/cco-2026-1-0021

Free full text

Authors (2)

Michael Canonico, Somedeb Ball

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Canonico, M., Ball, S. (2026). Back to the future: “7+3” joins the venetoclax plus intensive chemotherapy movement. Chinese Clinical Oncology. https://doi.org/10.21037/cco-2026-1-0021

Related articles

• Eribulin and trastuzumab in early-line HER2-positive metastatic breast cancer: evaluating an active chemotherapy partner in an evolving treatment landscape · Chinese Clinical Oncology · 2026 · Same journal
• Genome-wide 5-hydroxymethylcytosine in circulating cell-free DNA reflects DNA methylation dynamics for non-invasive detection of early hepatocellular carcinoma · Chinese Clinical Oncology · 2026 · Same journal
• Cadonilimab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a step forward for bispecific immunotherapy? · Chinese Clinical Oncology · 2026 · Same journal
• Advancing the frontiers of hepatocellular carcinoma treatment: a comprehensive review of past, ongoing, and future clinical trials · Chinese Clinical Oncology · 2026 · Same journal
• First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results · Chinese Clinical Oncology · 2026 · Same journal
• Protocol for the impact of medication therapy management on efficacy and safety of postoperative anticoagulation therapy in patients with colorectal cancer: an open-label, prospective and randomized clinical trial · Chinese Clinical Oncology · 2026 · Same journal
• Temporal evolution of liver cancer etiology in China, 1990–2021: insights from the Global Burden of Disease Study 2021 · Chinese Clinical Oncology · 2025 · Same journal
• Fos-related antigen 1 is required for Helicobacter pylori-induced inflammatory response in gastric epithelial cells through NF-κB pathway · Chinese Clinical Oncology · 2026 · Same journal
• Drug-induced liver injury and acute pancreatitis during trastuzumab therapy in a BRCA1-mutated, HER2-positive breast cancer patient: a case report · Chinese Clinical Oncology · 2026 · Same journal
• Combination therapy in sarcomas and the challenges of heterogeneity · Chinese Clinical Oncology · 2026 · Same journal